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CRIMES AND OFFENSES 
Controlled Substances: Amend Chapter 13 of Title 16, Code 
Section 116.2 of Article 6 of Chapter 4 of Title 26, Article 1 of 
Chapter 2A of Title 31, Article 1 of Chapter 1 of Title 31, and 
Article 2 of Chapter 16 of Title 45 of the Official Code of Georgia 
Annotated, Relating to Controlled Substances, the Authority of 
Licensed Health Practitioners to Prescribe Opioid Antagonists and 
Immunity from Liability, the Obligations of the Department of 
Public Health, General Provisions for Health, and Death 
Investigations, Respectively, so as to Change Provisions Relating to 
the Use of the Electronic Data Base; Transfer Responsibilities for 
the Electronic Data Base of Prescription Information of the 
Georgia Drugs and Narcotics Agency to the Department of Public 
Health; Provide for the Department’s Authority to Continue the 
Maintenance and Development of the Electronic Data Base of 
Prescription Information; Provide for Definitions; Collect More 
Information Regarding the Dispensing and Use of Certain 
Controlled Substances; Change the Frequency of Reporting 
Certain Prescriptions in the Electronic Data Base of Prescription 
Information; Clarify Provisions Relating to Confidentiality; 
Change Provisions Relating to Liability and Duties; Change 
Provisions Relating to the Definitions of Dangerous Drugs; 
Require the Department of Public Health Have Responsibility for 
the Electronic Prescription Monitoring Data Base; Provide for 
Information to Patients by Prescribers when Prescribing Opioids; 
Provide for Immunity for the State Health Officer under Certain 
Circumstances; Change Provisions Relating to the State Health 
Officer; Provide for His or Her Authority in Connection to Certain 
Dangerous Drugs; Provide for a Coroner’s Inquest when an 
Individual Dies of a Suspected Drug Overdose; Amend Section 2 of 
Chapter 12 of Title 31 of the Official Code of Georgia Annotated, 
Relating to Reporting Disease, Confidentiality, Reporting Required 
by Pharmacists, Immunity from Liability as to Information 
Supplied, and Notification of Potential Bioterrorism, so as to Add 
Neonatal Abstinence Syndrome Reporting; Amend Chapter 5 of 
Title 26 of the Official Code of Georgia Annotated, Relating to 
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Drug Abuse Treatment and Education Programs, so as to Provide 
for Annual Inspection; Provide for Annual Reporting of Certain 
Data; Amend Part 2 of Article 6 of Chapter 2 of Title 20 of the 
Official Code of Georgia Annotated, Relating to Competencies and 
Core Curriculum in Elementary and Secondary Education, so as to 
Give a Short Title to a Code Section Relating to Cardiopulmonary 
Resuscitation and Use of Automated External Defibrillators in 
Schools; Provide for a Short Title; Provide for Related Matters; 
Repeal Conflicting Laws; and for Other Purposes  
CODE SECTIONS: O.C.G.A. §§ 16-13-56.1 (new); -57, 
-58, -59, -60, -61, -62, -63, -64, 
-65 (amended); -71 (amended); 
20-2-149.1 (amended); 26-4-116.2 
(amended); 26-5-22 (new); -23 (new); 
31-1-10 (amended); 
31-2A-4 (amended); 
31-12-2 (amended); 
45-16-24 (amended); 
45-16-27 (amended) 
BILL NUMBER: HB 249 
ACT NUMBER: 141 
GEORGIA LAWS: 2017 Ga. Laws 319 
SUMMARY: The Act amends Georgia’s controlled-
substances statutes to expand medical 
provider requirements to record 
prescription drug information in an 
electronic prescription drug monitoring 
program database (PDMP). Medical 
providers are now required to use the 
PDMP to enter information about their 
prescription of certain types and 
quantities of opioids. The purpose of 
the act is to fight Schedule II opioid 
abuse throughout the state of Georgia. 
A medical provider’s failure to report 
required information is reported to his 
or her respective state regulatory board 
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for possible reprimand. In addition to 
mandatory reporting, the Act includes 
various other provisions related to 
regulating opioid misuse. The Act 
removes naloxone’s codification as a 
dangerous drug when naloxone is used 
for overdose prevention. Additionally, 
the Act requires law enforcement 
officers to notify the coroner or county 
medical examiner of apparent drug 
overdoses. Finally, the Act adds a name 
to a separate Code section regarding 
cardiopulmonary resuscitation and use 
of automated defibrillators. 
Effective Date: July 1, 2017 
History 
Drug abuse is a serious public health concern.1 In fact, having 
supplanted car accident fatalities in 2008,2 “drug overdose deaths are 
the leading cause of injury death in the United States.”3 Opioid 
misuse is of particular concern, as more than 60% of all overdose 
deaths are related to opioid abuse.4 Although the epidemic has been a 
concern for decades,5 the crisis has significantly worsened over the 
past five years.6 In response to this concern, states are looking to curb 
the epidemic and find solutions to protect their citizens.7 
                                                                                                                 
 1. Drug Overdose Death Data, CTRS. FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/drugoverdose/data/statedeaths.html (last updated Dec. 16, 2016) (finding a 
statistically significant increase in overdose death rates from 2014 to 2015 in 19 States). 
 2. DEA: Drug Overdoses Are Leading Cause of US Injury Deaths, VOA NEWS (Nov. 5, 2015, 
11:32 AM), https://www.voanews.com/a/dea-drug-overdoses-are-leading-cause-of-us-injury-
deaths/3038150.html. 
 3. The U.S. Opioid Epidemic, U.S. DEP’T OF HEALTH & HUMAN SERVS., 
https://www.hhs.gov/opioids/about-the-epidemic/#us-epidemic (last visited May 27, 2017). 
 4. Understanding the Epidemic, CTRS. FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/drugoverdose/epidemic/ (last updated Dec. 16, 2016). 
 5. Drug overdose deaths increased by 33-percent in past 5 years, FOX NEWS (Dec. 17, 2016), 
http://www.foxnews.com/health/2016/12/17/drug-overdose-deaths-increased-by-33-percent-in-past-5-
years.html (“Drug overdose deaths have increased by 33 percent in the past five years across the 
country, with some states seeing jumps of nearly 200 percent.”). 
 6. See Understanding the Epidemic, supra note 4 (stating that the number of overdose deaths in the 
3
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Georgia is one of the states experiencing an increase in opioid 
abuse.8 The state experienced a tenfold increase in prescription 
opioid overdose deaths between 1999 and 2014, and Georgia remains 
among the top eleven states with the most prescription opioid 
overdose deaths.9 In 2016, 549 people died from prescription drug 
overdose—a rate of more than one-and-a-half Georgians per day.10 
According to Representative Kevin Tanner (R-9th), everyone shares 
the concern over opioid abuse because most everyone has been 
personally affected by addiction or overdose.11 
Because of these unfortunate statistics, Georgia has recently 
considered programs to help those affected by opioid abuse.12 In 
2011, Georgia implemented a Prescription Drug Monitoring Program 
(PDMP),13 a tool employed by nearly every state.14 A PDMP is an 
electronic database used by the state to collect and analyze 
prescription drug information for “misuse, abuse, and patterns of 
controlled substance prescribing” by doctors.15 Collecting this data 
gives prescribers access to the prescription history of their patients so 
                                                                                                                 
United States has quadrupled in the past seventeen years). 
 7. See Diane Yap, As governments respond to Rx drug abuse, pharmacists and their patients face 
challenges, AM. PHARMACISTS ASS’N (Oct. 1, 2015), https://www.pharmacist.com/governments-
respond-rx-drug-abuse-pharmacists-and-their-patients-face-challenges (discussing how the federal 
government, state governments, and pharmacists are all struggling to find methods to curb opioid 
abuse). 
 8. SUBSTANCE ABUSE RESEARCH ALL., PRESCRIPTION OPIOIDS AND HEROIN EPIDEMIC IN GEORGIA 
5 (2017), http://www.senate.ga.gov/sro/Documents/StudyCommRpts/OpioidsAppendix.pdf (discussing 
the tenfold increase of prescription opioid overdose deaths between 1999 and 2014). 
 9. Id. 
 10. Id. at 6 fig. 3. 
 11. Interview with Rep. Kevin Tanner (R-9th) at 7 min., 27 sec. (Mar. 22, 2017) (on file with 
Georgia State University Law Review) [hereinafter Tanner Interview]. 
 12. Jared Bruff & Megan Daugherty, Crimes and Offenses: Controlled Substances, 28 GA. ST. U. L. 
REV. 269, 270–71 (2011) (discussing how Georgia lagged in establishing legislation to prevent pill 
mills, or providers who prescribe painkillers inappropriately). 
 13. See Prescription Drug Monitoring Frequently Asked Questions (FAQ), PRESCRIPTION DRUG 
MONITORING PROGRAM & TECHNICAL ASSISTANCE CTR., 
http://www.pdmpassist.org/content/prescription-drug-monitoring-frequently-asked-questions-faq (last 
visited May 27, 2017) (stating forty-nine states and the District of Columbia currently have an 
operational prescription drug monitoring database). 
 14. Bruff & Daugherty, supra note 12, at 281–82 (discussing the creation of the PDMP by Act 229 
in 2011). 
 15. Georgia Prescription Drug Monitoring Program, GA. DRUGS & NARCOTICS AGENCY, 
https://gdna.georgia.gov/georgia-prescription-drug-monitoring-program (last visited May 27, 2017). 
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they can identify trends or provide early intervention to their patients, 
if necessary.16 
Despite the seemingly beneficial attributes of the database, 
Georgia’s original law included a flaw that reduced its impact: no 
physician was required to register or participate in the PDMP under 
the 2011 legislation.17 As of the end of Georgia’s 2017 legislative 
session, only 25% of practicing physician prescribers had registered 
for the database, and only 12% of practicing physician prescribers 
actively used the database.18 Georgia’s PDMP was fully operational 
in 2013 when the program received funding,19 yet 2014 was 
Georgia’s deadliest year on record, with 588 prescription opioid 
overdose deaths—a 33% increase over 2013.20 Therefore, faced with 
a continuously-growing opioid epidemic, Georgia state legislators 
began looking for new options to address overdose deaths only five 
years after implementing the PDMP.21 
On December 14, 2016, Georgia Governor Nathan Deal (R) issued 
an executive order aimed at curbing the epidemic by allowing 
pharmacies to dispense naloxone over-the-counter.22 Naloxone is a 
                                                                                                                 
 16. Prescription Drug Monitoring Programs (PDMP), CTRS. FOR DISEASE CONTROL & 
PREVENTION, https://www.cdc.gov/drugoverdose/pdmp/ (last updated Mar. 21, 2017). 
 17. See 2011 Ga. L. 659, § 2, at 665 (formerly found at O.C.G.A. § 16-13-57 (2016)). This section of 
the 2011 legislation created the PDMP. Id. Nothing in the statute required physician participation. See 
id.; see also 2016 Public Policy Agenda for Georgia Pharmacists, FRANCES CULLEN, P.C. (July 19, 
2016), http://www.francullen.com/Blog/2016-Public-Policy-Agenda-for-Georgia-Pharmacists.shtml 
(“Currently, only pharmacists are required to enter Schedule II prescriptions into PDMP; accessing the 
system is voluntary for physicians. This means that patients are still falling through the cracks.”). 
 18. Tanner Interview, supra note 11, at 2 min., 30 sec. (“They aren’t required to use [the database]. 
So only 25% or so of the doctors have registered to use the database. And out of that only about half of 
those are using it. So about 12%.”). 
 19. 2016 Public Policy Agenda for Georgia Pharmacists, supra note 17 (“The PDMP was initially 
funded in 2013 through a $400,000 grant from the Bureau of Justice Assistance, so there was no cost to 
the state of Georgia.”). There was concern from the beginning about whether the PDMP would be 
functional. Bruff & Daugherty, supra note 12, at 292. The funding came two years after the inception of 
the database. Id. (“If the Agency is successful in obtaining funding, the program may be operational by 
2013. If not, the program may just be a great idea that never comes to life.”). 
 20. SUBSTANCE ABUSE RESEARCH ALL., supra note 8 at 6 fig. 3 (2017), 
http://www.senate.ga.gov/sro/Documents/StudyCommRpts/OpioidsAppendix.pdf (discussing the 
number of prescription opioid overdose deaths in Georgia). 
 21. Tanner Interview, supra note 11, at 5 min., 12 sec. (“I started working on this issue about a year 
ago actively.”). 
 22. Press Release, Office of the Governor, Deal Expands Access to Emergency Tool to Parents to 
Help Fight Opioid Epidemic (Dec. 14, 2016), https://gov.georgia.gov/press-releases/2016-12-14/deal-
expands-access-emergency-tool-parents-help-fight-opioid-epidemic (discussing Governor Deal’s 
standing order to allow naloxone to be dispensed over-the-counter). 
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drug administered to individuals experiencing a drug overdose.23 If 
timely administered, the drug can reverse the effects of an opioid 
overdose and thus save the life of the overdosing individual.24 The 
Governor’s proactive step to lessen overdoses and make the “drug 
accessible to anyone in a position to assist persons at risk of overdose 
will save countless lives.”25 
By the time the 2017 legislative session arrived, legislators were 
also considering options to further address the opioid epidemic.26 
Two legislators in particular spearheaded the effort: Representative 
Kevin Tanner and Senator Renee Unterman (R-45th).27 Because the 
opioid epidemic involves more than doctors inappropriately 
prescribing prescription painkillers, the General Assembly addressed 
various issues in one bill.28 These issues included the following: (1) 
the voluntary nature of the PDMP,29 (2) the existing naloxone 
executive order,30 and (3) the difficulty of tracking the overdose 
deaths across the state.31 To address each of these concerns, the 
Georgia General Assembly passed House Bill (HB) 249 and created a 
more expansive program to fight Georgia’s opioid epidemic.32 
                                                                                                                 
 23. See Press Release, Ctrs. for Disease Control & Prevention, Expanding Naloxone Use Could 
Reduce Overdose Deaths and Save Lives (Apr. 24, 2015), 
https://www.cdc.gov/media/releases/2015/p0424-naloxone.html (discussing how Emergency Medical 
Services staff administer naloxone to individuals suffering opioid overdose). 
 24. Id. 
 25. Joshua Silavent, Georgia Pharmacists Given OK to Dispense Anti-Overdose Drug, GAINESVILLE 
TIMES (Dec. 16, 2016, 12:30 AM), http://www.gainesvilletimes.com/archives/120885/ (discussing the 
order by the Governor). 
 26. Tanner Interview, supra note 11, at 12 min., 13 sec. (“[M]y work on this legislation didn’t start, 
and I know Senator Unterman’s did not start, the day session started. This has been a year-plus 
process.”). 
 27. Id. 
 28. Id. at 19 min., 15 sec. (“You know there’s other factors in this thing that makes it a more 
expansive bill than just about doctors having to check a database. And again, it’s kind of looking at this 
from a global perspective of, how can we turn the tide on opioid abuse?”). 
 29. Id. at 5 min., 43 sec. (“[O]ne of the things we saw that had worked in other states is when 
doctors are required to check the PDMP.”). 
 30. Video Recording of House Proceedings at 49 min., 33 sec. (Mar. 3, 2017) (remarks by Rep. 
Kevin Tanner (R-9th)), https://www.youtube.com/watch?v=TbSIN21fBss [hereinafter House 
Proceedings Video] (“One of the other things that [HB 249] does is codify that naloxone, which the 
Governor [] allowed through an executive order to be sold over-the counter.”). 
 31. Tanner Interview, supra note 11, at 6 min., 19 sec. (“[I]t’s important to know where those are 
occurring because we can respond with resources into those areas. But in Georgia, the coroners and the 
medical examiners are not required to report those to the Chief Medical Examiner office.”). 
 32. Press Release, Office of the Governor, Deal Signs Opioid Legislation (May 4, 2017), 
https://gov.georgia.gov/press-releases/2017-05-04/deal-signs-opioid-legislation (discussing Governor 
Deal signing HB 249 into law). 
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Bill Tracking of HB 249 
Consideration and Passage by the House 
Representatives Kevin Tanner (R-9th), Mark Newton (R-123rd), 
Jon Burns (R-159th), Jan Jones (R-47th), Andrew Welch (R-110th), 
and Bubber Epps (R-144th) sponsored HB 249 in the House.33 The 
House read the bill for the first time on February 7, 2017, and 
committed the bill to the House Judiciary Non-Civil Committee.34 
The House read the bill for the second time on February 8, 2017.35 
On February 27, 2017, the House Judiciary Non-Civil Committee 
favorably reported the bill by substitute.36 
The House Committee substitute reflected the authors’ desire to 
prevent “doctor-shopping” without unduly restricting doctors’ ability 
to prescribe needed medications.37 In response to conversations with 
Governor Nathan Deal and the Georgia Drugs and Narcotics Agency, 
which currently administers the prescription drug monitoring 
database, the Committee substitute shifted responsibility for the 
electronic database from that agency to the Department of Public 
Health.38 
                                                                                                                 
 33. Georgia General Assembly, HB 249, Bill Tracking, http://www.legis.ga.gov/legislation/en-
US/Display/20172018/HB/249. 
 34. State of Georgia Final Composite Status Sheet, HB 249, May 11, 2017. 
 35. Id. 
 36. Id. 
 37. Video Recording of House Judiciary Committee Non-Civil Division Meeting at 57 min, 48 sec. 
(Feb. 27, 2017) (remarks by Rep. Kevin Tanner (R-9th)), 
https://livestream.com/accounts/19771755/events/6810993/videos/150571239 [hereinafter House 
Judiciary Non-Civil Committee Video]. Representative Cooper shared concerns raised by constituents 
that the legislation may cause doctors to become overly cautious when prescribing opioids, reducing 
access to pain medications by those who need them, such as cancer patients. Id. at 54 min., 48 sec. 
(remarks by Rep. Sharon Cooper (R-43rd)). “Doctor-shopping” occurs when patients visit multiple 
prescribers to obtain prescriptions for drugs, like opioids, for illicit use. CTRS. FOR DISEASE CONTROL & 
PREVENTION, DOCTOR SHOPPING LAWS 1 (n.d.), https://www.cdc.gov/phlp/docs/menu-
shoppinglaws.pdf. 
 38. House Judiciary Non-Civil Committee Video, supra note 37, at 58 min., 42 sec. (remarks by 
Rep. Kevin Tanner (R-9th)). The change responds to a lack of resources within the Drugs and Narcotics 
Agency to support the database. Id. To reflect this change, the Committee substitute replaces the word 
“agency” with “department” throughout the bill. HB 249 (HCS) § 1-2, p. 2, ll. 31, 43, 57, 2017 Ga. Gen. 
Assemb.; id. p. 3, ll. 60, 63, 66, 68, 75, 95; id. p. 4, ll. 102, 104, 106, 109, 110, 114, 116, 122, 125, 127; 
id. p. 5, ll. 137, 144, 148; id. p. 7, ll. 224, 234, 240; id. p. 8, ll. 248, 253; HB 249 (HCS) p. 9, ll. 286–87, 
2017 Ga. Gen. Assemb.; id. p. 10, l. 320; id. p. 11, l. 353. “Department” is defined as the Department of 
Public Health. See id. § 1-2, p. 2, l. 27–29. 
7
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Because current law does not require database enrollment, the 
House Committee substitute specified deadlines for prescriber 
enrollment in the prescription drug monitoring database.39 The 
Committee substitute also set testing standards for the database, 
because the new enrollment and usage requirements would 
drastically increase the number of users and overload the current 
system.40 
In addition, the House Committee substitute increases the 
frequency with which dispensers, such as pharmacists, must update 
required prescription information in the database to every twenty-
four hours.41 The Committee made this change because prescribers 
will now be required to check the database before prescribing certain 
drugs and will need the most up-to-date information to make 
informed decisions.42 The Committee substitute also inserted 
language that encourages, but does not require, dispensers to 
reference the prescription monitoring database to help detect the 
overprescribing of controlled substances, including opioids.43 
To ensure that the prescription information cannot be shared or 
misused, the House Committee substitute included language about 
protecting personal identification information in compliance with the 
Health Insurance Portability and Accessibility Act (HIPAA).44 This 
language is repeated later in the bill, relating to the inclusion of 
                                                                                                                 
 39. Id. § 1-2, p. 2, ll. 44–49. According to the authors, only about 25% of prescribers are currently 
registered to use the database, and only half of those who are registered actually use the database. House 
Judiciary Non-Civil Committee Video, supra note 37, at 59 min., 50 sec. (remarks by Rep. Kevin 
Tanner (R-9th)). 
 40. HB 249 (HCS) § 1-2, p. 2, ll. 50–55, 2017 Ga. Gen. Assemb.; House Judiciary Non-Civil 
Committee Video, supra note 37, at 1 hr., 0 min., 22 sec. (remarks by Rep. Kevin Tanner (R-9th)). The 
House Committee substitute clarifies that the database monitoring requirements will only become 
effective if the database is certified as operable. HB 249 (HCS) § 1-2, p. 10, ll. 320–21, 2017 Ga. Gen. 
Assemb. 
 41. HB 249 (HCS) § 1-2, p. 4, ll. 97–100. 
 42. House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 1 min., 5 sec. (remarks by 
Rep. Kevin Tanner (R-9th)). 
 43. HB 249 (HCS) § 1-2, p. 9, ll. 295–98. (“[D]ispensers are encouraged to obtain [information 
about a patient from the prescription monitoring data base] while keeping in mind that the purpose of 
such data base includes reducing duplicative prescribing and overprescribing of controlled 
substances.”). 
 44. Id. § 1-2, p. 4, ll. 114–21; House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 1 
min., 40 sec. (remarks by Rep. Kevin Tanner (R-9th)). 
8
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prescription information in a patient’s electronic health or medical 
record.45 
The House Committee substitute also reflected concerns from 
hospitals about prescribers’ ability to balance the new monitoring 
requirements with their demanding workloads.46 To alleviate this 
concern, the Committee substitute granted prescribers the authority to 
designate up to two employees or contractors per shift who may 
access the database and provide the required prescription information 
on the prescriber’s behalf.47 The House Committee substitute 
mandates, rather than permits, steps the Department of Public Health 
must take when a prescriber reports a patient’s “usage, misuse, abuse, 
or underutilization of a controlled substance.”48 
The authors of the House Committee substitute wanted to narrowly 
tailor the legislation to include only those drugs that raise concerns 
about abuse, overdose, or addiction.49 Therefore, the House 
Committee substitute required that prescribers log specific 
benzodiazepines in the database: diazepam (e.g., Valium), 
alprazolam (e.g., Xanax), and lorazepam (e.g., Ativan).50 Further, the 
Committee substitute clarified that prescribers do not have to check 
the database before prescribing Schedule II drugs unless the 
legislation specifies otherwise.51 Finally, the House Committee 
specified those instances when a prescriber does not need to check 
the database.52 The changes aimed to incentivize doctors to refrain 
                                                                                                                 
 45. HB 249 (HCS) § 1-2, p. 7, ll. 223–24, 2017 Ga. Gen. Assemb.; compare id. § 1-2, p. 7, ll. 225–
28, with id. § 1-2, p. 4, ll. 114–21. 
 46. House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 2 min., 21 sec. (remarks by 
Rep. Kevin Tanner (R-9th)). 
 47. HB. 249 (HCS), § 1-2, pp. 6–7, ll. 202–07. These designees may include a registered nurse, 
officer manager, or other employee or contractor who has been appropriately screened. See House 
Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 2 min. 53 sec. (remarks by Rep. Kevin 
Tanner (R-9th)). 
 48. HB. 249 (HCS), § 1-2, p. 7, l. 214, 2017 Ga. Gen. Assemb. (changing “may” to “shall”). 
 49. See House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 10 min., 3 sec. 
(remarks by Rep. Kevin Tanner (R-9th)). 
 50. HB. 249 (HCS), § 1-2, p. 9, ll. 306–07. 
 51. Id. § 1-2, p. 10, ll. 334–37 (requiring prescribers to check the database for prescriptions of “those 
controlled substances listed in paragraph (1) or (2) of Code section 16-13-26 and benzodiazepines, 
including only diazepam, alprazolam, or lorazepam.”). 
 52. Id. § 1-2, pp. 9–10, ll. 309–117. The exceptions include prescriptions for a three-day supply (no 
more than twenty-six pills), prescriptions given to patients while being treated in a hospital or health 
care facility, such as a nursing home, or a ten-day supply (no more than forty pills) for patients who 
have had outpatient surgery. Id. 
9
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from overprescribing these medicines, focusing on instances where 
doctor-shopping is a concern.53 The House Committee substitute also 
required prescribers to provide information to patients about the risk 
of opioid abuse and options for safe disposal of unused opioids.54 
The House read the bill for the third time on March 3, 2017.55 
Representative Tanner and Representative Rich Golick (R-40th) 
offered a floor amendment that made minor changes to certain terms 
used throughout the House Committee substitute bill to add clarity, 
ensure consistency, and correct a typographical error.56 The 
amendment was adopted.57 The House passed the Committee 
substitute, as amended, on March 3, 2017, by a vote of 167 to 1.58 
Consideration and Passage by the Senate 
Senator Renee Unterman (R-45th) sponsored HB 249 in the 
Senate.59 The Senate first read HB 249 on March 3, 2017.60 The 
Senate assigned it to the Senate Committee on Health and Human 
Services.61 The Committee on Health and Human Services favorably 
reported the bill by substitute on March 20, 2017.62 
The Senate Committee substitute reflects the collaboration of 
Senator Unterman and Representative Tanner.63 Most significantly, 
                                                                                                                 
 53. House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 7 min., 5 sec. (remarks by 
Rep. Kevin Tanner (R-9th)). 
 54. HB. 249 (HCS), § 2-1, p. 13, ll. 422–25, 2017 Ga. Gen. Assemb. The Committee substitute also 
defines “opioids” as used in the legislation. Id. § 2-1, p. 13, ll. 420–21. 
 55. State of Georgia Final Composite Status Sheet, HB 249, May 11, 2017. 
 56. House Proceedings Video, supra note 30, at 51 min., 3 sec. (Mar. 3, 2017) (remarks by Rep. 
Tanner (R-9th)); id. at 52 min. (clerk’s reading of amendment by Rep. Tanner and Rep. Golick (R-
40th)). The Committee substitute contained a typographical error throughout the bill, replacing 
references to “data base,” “program,” and “program established pursuant to Code section 16-13-59” 
with the incorrect acronym. House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 12 
min., 36 sec.; House Floor Amendment to HB 249 (AM 29 2594), introduced by Reps. Rich Golick (R-
45th) and Kevin Tanner (R-9th), Mar. 3, 2017. 
 57. House Proceedings Video, supra note 30, at 53 min., 26 sec. (Mar. 3, 2017) (remarks by Rep. 
David Ralston (R-7th)). 
 58. Georgia House of Representatives Voting Record, HB 249, #186 (Mar. 3, 2017). 
 59. Georgia General Assembly, HB 249, Bill Tracking, http://www.legis.ga.gov/legislation/en-
US/Display/20172018/HB/249. 
 60. State of Georgia Final Composite Status Sheet, HB 249, May 11, 2017. 
 61. Id. 
 62. Id. 
 63. Audio Recording of Senate Health and Human Services Committee at 14 min., 5 sec. (Mar. 16, 
2017) (remarks by Sen. Unterman) (on file with the Georgia State University Law Review). 
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the Senate Committee substitute deleted the language limiting the 
types of benzodiazepines covered by the legislation, thus expanding 
the number of prescription drugs triggering the requirement to check 
the database.64 In addition, the Senate Committee substitute adds 
prescriptions for terminally-ill patients to the list of instances where 
prescribers do not have to review the PDMP before writing a 
prescription.65 
The Senate Committee substitute allowed a state health officer to 
permit and set standards for the prescription of opioid antagonists, 
such as naloxone (e.g., Narcan).66 The Committee substitute required 
the state health officer be a licensed medical practitioner in 
Georgia.67 The Committee intended this change to incorporate the 
Governor’s executive order relating to naloxone.68 
Mirroring a provision in Senator Unterman’s failed bill,69 the 
Committee substitute defined “neonatal abstinence syndrome” and 
established notice and reporting requirements when patients exhibit 
symptoms of the syndrome.70 
The Senate Committee substitute also created two new 
requirements related to licensed narcotic treatment programs.71 First, 
it required annual inspection of all licensed narcotic treatment 
programs.72 Second, it called for an annual report of the number of 
patients enrolled in and discharged from drug abuse treatment 
programs.73 
The Senate read the bill for the second time on March 20, 2017, 
and for the third time on March 22, 2017.74 No Senate floor 
amendments were introduced, and, on March 22, 2017, the Senate 
                                                                                                                 
 64. Compare HB 249 (HCSFA), § 1-2, p. 9, ll. 306–07, 2017 Ga. Gen. Assemb., with HB 249 
(SCS), § 1-2, p. 10, ll. 323–24, 2017 Ga. Gen. Assemb. The same changes were made to identical 
language found later in the bill. Compare HB 249 (HCSFA), § 1-2, p. 10, ll. 336–37, 2017 Ga. Gen. 
Assemb., with HB 249 (SCS), § 1-2, p. 11, ll. 353–55, 2017 Ga. Gen. Assemb. 
 65.  HB 249 (SCS), § 1-2, p. 10, l. 336, 2017 Ga. Gen. Assemb. 
 66. Id. § 3-2, p. 15, ll. 487–89. 
 67. Id. § 3-2, p. 15, ll. 482–83. 
 68. See Audio Recording of Senate Health and Human Services Committee, supra note 63, at 21 
min., 51 sec (remarks by Senator Unterman). 
 69. Id. at 23 min., 6 sec.; see SB 81, § 3-1, pp. 10–11, ll. 311–27. 
 70. HB 249 (SCS), § 4-1, p. 15, ll. 496–508, 2017 Ga. Gen. Assemb. 
 71. Id. § 5-1, p. 16, ll. 511–26. 
 72. Id. § 5-1, p. 16, ll. 514–19. 
 73. Id. § 5-1, p. 16, ll. 520–26. 
 74. State of Georgia Final Composite Status Sheet, HB 249, May 11, 2017. 
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passed the Committee substitute of HB 249 without objection by a 
vote of 50 to 0.75 
Reconsideration and Passage by the House 
The Senate transmitted the bill to the House on March 22, 2016.76 
Representative Tanner offered a floor amendment to the Senate 
substitute, replacing “up to” with “a minimum of” on lines 422 and 
425, relating to naloxone dosages.77 On March 28, 2017, the House 
agreed to the Senate substitute with Representative Tanner’s 
amendment by a vote of 164 to 9.78 The same day, the House 
transmitted the bill to the Senate, and the Senate agreed to the House 
amendment to the Senate Committee substitute, passing the bill by a 
vote of 50 to 0.79 
The House sent the bill to Governor Nathan Deal (R) on April 7, 
2017.80 The Governor signed the bill into law on May 4, 2017, and 
the bill became effective on July 1, 2017.81 
The Act 
The Act amends the following portions of the Official Code of 
Georgia Annotated: Chapter 13 of Title 16, relating to controlled 
substances; Section 116.2 of Article 6 of Chapter 4 of Title 26, 
relating to the authority to prescribe opioids; Section 4 of Article 1 of 
Chapter 2A of Title 31, relating to the Department of Public Health; 
Article 1 of Chapter 1 of Title 31, relating to the general health 
provisions; Article 2 of Chapter 16 of Title 45, relating to death 
investigations; Section 2 of Chapter 12 of Title 31, relating to 
reporting disease; Chapter 5 of Title 26, relating to drug abuse 
                                                                                                                 
 75. Georgia Senate Voting Record #217, HB 249 (Mar. 22, 2017). 
 76. State of Georgia Final Composite Status Sheet, HB 249, May 11, 2017. 
 77. House Floor Amendment to HB 249 (AM 29 2626), introduced by Rep. Kevin Tanner (R-45th), 
Mar. 3, 2017. 
 78. Georgia House of Representatives Voting Record #348, HB 249 (Mar. 28, 2017). 
 79. Georgia Senate Voting Record #320, HB 249 (Mar. 28, 2017). 
 80. State of Georgia Final Composite Status Sheet, HB 249, May 11, 2017. 
 81. O.C.G.A. § 1-3-4(a)(1) (2017) (“Any Act which is approved by the Governor or which becomes 
law without his approval on or after the first day of January and prior to the first day of July of a 
calendar year shall become effective on the first day of July”); State of Georgia Final Composite Status 
Sheet, HB 249, May 11, 2017. 
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treatment and education programs; and Part 2 of Article 6 of Chapter 
2 of Title 20, relating to use of automated external defibrillators in 
schools.82 
Part 1 
Section 1-1 of the Act, styles the Act as the “Jeffrey Dallas Gay, 
Jr., Act,”83 and most of the remaining sections of Part 1 amend 
Chapter 13 of Title 16, relating to the electronic prescription drug 
monitoring program database.84 
First, this part of the Act adds two definitions to Code section 
16-13-57: “Department,” referring to the Department of Public 
Health, and “PDMP,” referring to the prescription drug monitoring 
database.85 The Act updates these terms throughout the Code for 
consistency.86 
The Act adds subsections (c) and (d) to Code section 16-13-57.87 
Subsection (c) requires prescribers with a current DEA registration 
number to enroll in the PDMP no later than January 1, 2018.88 
Prescribers who receive a DEA registration number after January 1, 
                                                                                                                 
 82. 2017 Ga. Laws 319, at 319–20. Section 7 of the Act adds a short title to O.C.G.A. § 20-2-149.1: 
the “Cory Joseph Wilson Act.” Id. at 335. This section of the Act was originally introduced as SB 245 
by Senators Butch Miller (R-49th), Renee Unterman (R-45th), Dean Burke (R-11th), Ben Watson 
(R-1st), Chuck Hufstetler (R-52nd), and Steve Henson (D-41st). Georgia General Assembly, SB 245, 
Bill Tracking, http://www.senate.ga.gov/senators/en-US/Member.aspx?Member=21&Session=25. The 
bill did not progress beyond second readers, and died on cross-over day. State of Georgia Final 
Composite Sheet, SB 245, May 11, 2017. Instead, the Senate Health and Human Services Committee, 
where SB 245 originated, added the exact language of SB 245 to the Senate Committee Substitute of HB 
249. Audio Recording of Senate Health and Human Services Committee, supra note 63, at 23 min., 42 
sec. (remarks by Senator Unterman). 
 83. 2017 Ga. Laws 319, § 1-1, at 320; See Derreck Booth, Sen. Miller Reflects on Legislation to 
Save Lives, ACCESSWDUN (Mar. 26, 2017), http://accesswdun.com/article/2017/3/517344/sen-miller-
reflects-on-legislation-to-save-lives. Senator Miller’s legislation, SB 121, relating to over-the-counter 
access to naloxone, is also titled the Jeffrey Dallas Gay, Jr. Act. 2017 Ga. Laws 22, § 1, at 22. Section 1-
3 and 1-4 of HB 249 applies to the same Chapter and Title of the Code as SB 121, and therefore falls 
within the Act. Compare 2017 Ga. Laws 21, §§ 1–3, at 22–23, with 2017 Ga. Laws 319, §§ 1-3 to 1-5, 
at 329–30. The Act is named in honor of a young Gainesville, Georgia man who died in 2012 as a result 
of prescription drug addiction and overdose. Booth, supra. Gay’s family has been active in advocating 
for opioid abuse awareness and prevention since his death. Id. 
 84. See 2017 Ga. Laws 319, §§1-2 to 1-4, at 320–29. 
 85. O.C.G.A. § 16-13-57 (Supp. 2017). 
 86. O.C.G.A §§ 16-13-57 to -64 (Supp. 2017). 
 87. 2017 Ga. Laws 319, §1-2, at 321. 
 88. O.C.G.A. § 16-13-57(c) (Supp. 2017). 
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2018, must register for the PDMP within 30 days.89 The subsection 
includes an administrative penalty for failure to comply with the 
registration deadline.90 Subsection (d) requires the Department of 
Public Health to randomly test the PDMP during a three-month 
period to ensure it is accessible and operational.91 
The Act, addressing privacy concerns related to the sharing and 
misuse of PDMP information, amends Code section 16-13-59(e) to 
require that the Department of Public Health remove personally 
identifying information from any prescription records retained by the 
Department.92 
The Act deletes the existing language about delegates of 
authorized prescribers and dispensers in Code section 16-13-60.93 
The Act replaces this language with a subsection permitting the 
prescriber to authorize up to two individuals meeting specified 
criteria to provide prescription information in accordance with Code 
section 16-13-59.94 
The Act adds a pharmacist from the State Board of Pharmacy and 
a representative from the Department of Public Health to the list of 
Electronic Database Review Advisory Committee members.95 
In Code section 16-13-63, subsection (a)(1) clarifies that 
dispensers are not required to reference the PDMP before dispensing 
a prescription to a patient.96 However, the amended Code section also 
emphasizes that the “purpose of such data base includes reducing 
duplicative prescribing and overprescribing of controlled substances” 
                                                                                                                 
 89. Id. 
 90. Id. (“A prescriber who violates this subsection shall be held administratively accountable to the 
state regulatory board governing such prescriber for such violation.”). For example, a physician will be 
penalized by the medical board. House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 9 
min., 18 sec. (remarks by Rep. Kevin Tanner (R-9th)). 
 91. O.C.G.A. § 16-13-57(d) (Supp. 2017); see also House Judiciary Non-Civil Committee Video, 
supra note 37, at 1 hr., 0 min., 30 sec. (remarks by Rep. Kevin Tanner (R-9th)), (discussing concerns 
that increased traffic will overload the current database and determining it is necessary monitor the 
technology). 
 92. O.C.G.A. § 16-13-59(e) (Supp. 2017); House Judiciary Non-Civil Committee Video, supra note 
37, at 1 hr., 1 min., 42 sec. (remarks by Rep. Kevin Tanner (R-9th)) (“One of the things we want to 
make very sure of is that the department cannot share this information, this private information.”). 
 93. 2017 Ga. Laws 319, §1-2, at 323. 
 94. 2017 Ga. Laws 319, § 1-2, at 323–26; O.C.G.A. § 16-13-60 (Supp. 2017); see discussion supra 
notes 46–48 (addressing hospitals’ concerns that prescribers be able to balance the new database 
requirement with their demanding workload). 
 95. O.C.G.A. § 16-13-61(b)(11) to -(12) (Supp. 2017). 
 96. O.C.G.A. § 16-13-63(a)(1) (Supp. 2017). 
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and encourages dispensers to check the database.97 Thus, although 
dispensers are not required to check the database before dispensing a 
controlled substance, this Code section encourages dispensers to do 
so to help detect and combat overprescribing of controlled substances 
like opioids. 
Subsection (a)(2) of Code section 16-13-63 requires a prescriber 
check the PDMP the first time he or she prescribes a controlled 
substance to a patient and at least once every ninety days thereafter, 
with several exceptions.98 Violators of this subsection are subject to 
administrative action by the regulatory board governing the 
prescriber.99 Subsection (b) provides a cause of action for any injury 
sustained because of a violation of subsection (a) and allows for 
attorneys’ fees.100 The previous version of this Code section did not 
provide a private cause of action based on violation of the Code 
section.101 
The Act codifies Governor Deal’s executive order authorizing 
over-the-counter access to naloxone in Code section 16-13-71.102 
Naloxone, commonly marketed under the brand names Narcan and 
Evzio, is an opioid antagonist, meaning it can rapidly reverse opioid 
overdoses.103 The new subsection exempts naloxone from the 
definition of a dangerous drug when used for drug overdose 
prevention or when dispensed in certain quantities, thus allowing 
greater access.104 
Finally, Section 1-5 of the Act adds subsection (15) to Code 
section 31-2A-4, relating to obligations of the Department of Public 
Health.105 This subsection transfers responsibility for the 
                                                                                                                 
 97. Id. 
 98. O.C.G.A. § 16-13-63(a)(2). The exceptions are discussed supra note 52. 
 99. O.C.G.A. § 16-13-63(a)(2)(C). The penalty is at the discretion of the administrative board 
governing the prescriber (i.e., the state medical board determines the penalty for a physician who 
violates this provision). See House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 9 
min., 18 sec. (remarks by Rep. Kevin Tanner (R-9th)). 
 100. O.C.G.A. § 16-13-63(b). Similar language was deleted from Code section 16-13-4(d). 2017 Ga. 
Laws 319–20. 
 101. 2017 Ga. Laws 319. 
 102. O.C.G.A. § 16-13-71(b)(635), -(c)(14.25); House Judiciary Non-Civil Committee Video, supra 
note 37, at 1 hr., 10 min., 33 sec. (Remarks by Rep. Kevin Tanner (R-9th)). 
 103. Opioid Overdose Reversal with Naloxone (Narcan, Evzio), NAT’L INST. HEALTH (Sept. 2016), 
https://www.drugabuse.gov/related-topics/opioid-overdose-reversal-naloxone-narcan-evzio. 
 104. O.C.G.A. § 16-13-71(c)(14.25). 
 105. 2017 Ga. Laws 319, § 1-5, at 330. 
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maintenance and administration of the PDMP to the Department.106 
Previously, the Georgia Drugs and Narcotics Agency maintained and 
administered the database.107 
Part 2 
Section 2-1 of the Act amends Chapter 13 of Title 16, relating to 
controlled substances, adding a definition of “opioids.”108 
Additionally, the new Code section requires prescribers to provide 
information to patients about the risks of addiction and safe disposal 
when prescribing opioids.109 This information may be communicated 
orally or in writing, such as through a pamphlet.110 
Part 3 
Part 3 amends Code section 31-1-10, creating additional 
requirements for and giving additional duties to the state health 
officer.111 Most significantly, the Act gives the health officer 
authority to set standards for the prescription of opioid antagonists, 
like naloxone.112 Finally, state health officers are immunized from 
liability for actions performed under this section.113 
                                                                                                                 
 106. O.C.G.A. § 31-2A-4(15) (Supp. 2017). 
 107. House Judiciary Non-Civil Committee Video, supra note 37, at 58 min., 45 sec. (Remarks by 
Rep. Kevin Tanner (R-9th)). 
 108. 2017 Ga. Laws 319, § 2-1, at 330. 
 109. O.C.G.A. § 16-13-56.1 (Supp. 2017). 
 110. House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 11 min., 25 sec. (Remarks 
by Rep. Kevin Tanner (R-9th)). This requirement is drafted broadly and does not specify how much 
information must be provided or from what sources prescribers should derive this information. See 
O.C.G.A. § 16-13-56.1. 
 111. 2017 Ga. Laws 319, § 3-1, at 330. This Section also updates Code section 26-4-116.2 by adding 
references to Code section 31-1-10. 2017 Ga. Laws 319, § 3-1, at 330–31. 
 112. O.C.G.A. § 31-1-10 (Supp. 2017). 
 113. O.C.G.A. § 26-4-116.2(e)(3). Relating to immunity, the Act also changes the Code section’s 
language from “[t]he following individuals are immune” to “[t]he following individuals shall be 
immune,” and changes immunity from “criminal liability” to immunity from “criminal responsibility.” 
See 2017 Ga. Laws 319, § 3-1, at 330–31. 
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Part 4 
Section 4-1 of the Act amends Code section 31-12-2, creating 
reporting requirements for neonatal abstinence syndrome.114 The new 
subsections define the disease, require reporting cases of the disease 
to the Department of Public Health, and require the Department 
provide an annual report on the disease to state legislators.115 
Part 5 
Section 5-1 of the Act amends Chapter 5 of Title 26, adding two 
new Code sections.116 Code section 26-5-22 requires annual onsite 
inspections of all licensed narcotic treatment programs.117 Code 
section 26-5-23 requires annual reporting of the number of patients 
enrolled in and discharged from such treatment programs.118 These 
provisions will help with the legislation’s broad goal of collecting 
data about opioid addiction and overdose so that the State can better 
understand and react to the opioid epidemic.119 
Part 6 
Section 6-1 of the Act amends Article 2 of Chapter 16 of Title 45, 
requiring any death resulting from an apparent drug overdose be 
immediately reported to the coroner or medical examiner of the 
county where the death occurred.120 This change will allow the 
Georgia Bureau of Investigation to identify patterns of opioid 
overdose and allocate resources accordingly.121 
                                                                                                                 
 114. 2017 Ga. Laws 319, § 4-1, 331–32. Neonatal abstinence syndrome refers to medical 
complications that arise when a newborn, exposed to addictive substances in utero, experiences opioid 
withdrawal. Karen McQueen & Jodie Murphy-Oikonen, Neonatal Abstinence Syndrome, 375 NEW 
ENGL. J. MED. 2468, 2469 (2016). 
 115. O.C.G.A. § 31-12-2(a.1) (Supp. 2017). 
 116. 2017 Ga. Laws 319, § 5-1, at 332. 
 117. O.C.G.A. § 26-5-22 (Supp. 2017). 
 118. O.C.G.A. § 26-5-23 (Supp. 2017). 
 119. See House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 12 min, 6 sec. 
(Remarks by Rep. Kevin Tanner (R-9th)). 
 120. O.C.G.A. § 45-16-24(a)(10) (Supp. 2017). Section 6 of the Act also amends Code section 
45-16-27 by replacing permissive language with mandatory language and the word “person” with 
“individual.” 2017 Ga. Laws 319. 
 121. House Judiciary Non-Civil Committee Video, supra note 37, at 1 hr., 12 min., 6 sec. 
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Analysis 
A PDMP with mandatory reporting introduces two important 
concerns for legislators: due process rights for physicians and privacy 
rights for physicians and their patients.122 Regarding due process, the 
General Assembly provided state regulatory boards the discretion to 
hold physicians accountable for violating the mandatory guidelines of 
the PDMP.123 This could create a situation where the prescribers 
believe they “have been denied due process [because] the board 
overstepped their authority [or] made the incorrect decision” and thus 
appeal the board’s decision. As for privacy rights, previous concerns 
about the privacy of patient information on the database are 
exasperated by the fact that more patients will now be entered into 
the system due to its mandatory nature.124 
Due Process Implications 
The new PDMP law creates a potentially worrisome situation 
where a physician could lose his or her license for failing to update 
the PDMP.125 Currently, state medical boards may revoke a license 
when the board determines a physician “overprescribes” 
painkillers.126 The new law, however, allows the board to revoke a 
physician’s license, not just for the affirmative act of overprescribing, 
but also for the passive act of failing to use the PDMP.127 
By giving the state medical board a new reason to revoke a 
physician’s livelihood, the PDMP may very well pose both 
substantive and procedural due process concerns.128 The Fifth 
                                                                                                                 
 122. Tanner Interview, supra note 11, at 2 min., 3 sec. (discussing the possibility of physicians losing 
their license due to a decision made by the medical board); id. at 13 min., 47 sec. (discussing the 
public’s concern about privacy and the legislation’s strong penalties for misusing the information). 
 123. O.C.G.A. § 16-13-63(a)(2)(C). 
 124. Tanner Interview, supra note 11, at 13 min., 17 sec. (discussing the public’s concern over 
privacy when the original legislation passed in 2011). 
 125. O.C.G.A. § 16-13-63(a)(2)(C) (Supp. 2017). 
 126. United States v. Ilayayev, 800 F. Supp. 2d 417, 434 (E.D.N.Y. 2011) (discussing how states 
regularly revoke licenses for overprescribing painkillers). 
 127. This bill does not address the over-prescription of opioids. In fact, Representative Kevin Tanner 
(R-9th) discussed a previous embodiment of the bill that limited the number of painkillers a physician 
could prescribe. Tanner Interview, supra note 11, at 16 min., 27 sec. Representative Tanner stated the 
bill should not “tell a doctor how to practice medicine.” Id. 
 128. See Rebecca L. Haffajee, Preventing Opioid Misuse with Prescription Drug Monitoring 
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Amendment of the United States Constitution protects an individual’s 
liberty and property interests from improper intrusion by the federal 
government.129 Additionally, the Fourteenth Amendment provides 
individuals this same protection from state governments.130 The due 
process required by the Fifth and Fourteenth Amendments provides 
both substantive and procedural due process rights.131 Substantive 
due process is the particular property or liberty interest that the 
constitution protects from unwarranted governmental intrusions, such 
as a physician’s right to make a living.132 Procedural due process 
protects the individual by providing appropriate procedures—such as 
notice and a fair hearing—if the government does deprive the 
individual of that interest.133 
If the PDMP raises substantive due process issues, the question is 
whether the state has adequate justification to enter the individual’s 
realm of interests.134 The state of Georgia gives the Georgia 
Composite Medical Board broad authority “[t]o revoke, suspend, 
issue terms and conditions, place on probation, limit practice, fine, 
require additional medical training, require medical community 
service, or otherwise sanction licensees . . . .”135 The Supreme Court 
of the United States agrees that the “[s]tates have a compelling 
interest in the practice of professions within their boundaries, 
and . . . as part of their power to protect the public health, safety, and 
other valid interests they have broad power to establish standards for 
licensing practitioners and regulating the practice of professions.”136 
Additionally, the United States Supreme Court has long held that 
states have broad powers to create regulations that promote public 
                                                                                                                 
Programs: A Framework for Evaluating the Success of State Public Health Laws, 67 HASTINGS L.J. 
1621, 1652–53 (2016). 
 129. U.S. CONST. amend. V (“No person shall...be deprived of life, liberty, or property, without due 
process of law.”). 
 130. U.S. CONST. amend. XIV, § 1 (“[N]or shall any state deprive any person of life, liberty, or 
property, without due process of law . . . .”). 
 131. See Haffajee, supra note 128, at 1653. 
 132. Carolyn R. Cody, Professional Licenses and Substantive Due Process: Can States Compel 
Physicians to Provide Their Services?, 22 WM. & MARY BILL RTS. J. 941, 942–43 (2014) (discussing 
how a license to practice is a protectable property interest). 
 133. See Haffajee, supra note 128, at 1653. 
 134. Id. 
 135. O.C.G.A § 43-34-5(c)(10) (2017). 
 136. Goldfarb v. Va. State Bar, 421 U.S. 773, 792 (1975). 
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health.137 Therefore, even though the new PDMP regulation may not 
be the same as a typical “overprescribing” issue faced by medical 
boards,138 most courts would likely agree that the PDMP is 
substantially related to promoting public health.139 For instance, the 
Supreme Court of California recently held that the government’s 
“interests in protecting the public from unlawful use and diversion of 
a particularly dangerous class of prescription drugs and protecting the 
patients from negligent or incompetent physicians” outweighs a 
physician’s interest in protecting her own right to privacy.140 
Procedural due process is also required if a physician is accused of 
violating the new PDMP laws. Georgia courts provide a broad 
standard for the medical board, and the Georgia Court of Appeals 
described the standard of review as follows: 
In order to comply with the requirements of due process, 
the hearing granted by an administrative body must be a 
full and fair one, before an impartial officer, board, or body 
free of bias, hostility, and prejudgment. The fact that the 
administrative agency is both the accuser and judge does 
not deprive [the] accused of due process of law, especially 
where an appeal from the determination of the agency may 
be had to the courts.141 
Therefore, the state medical board has broad discretion as long as 
the proceeding is “full and fair.”142 The opportunity to appeal further 
protects the accused.143 
                                                                                                                 
 137. Haffajee, supra note 128, at 1645 (noting that the ability of state governments to protect and 
preserve public health dates back to the Federalist Papers, and has been consistently upheld by the 
United States Supreme Court). 
 138. Failer v. Dep’t of Health, 139 So. 3d 359, 363 (Fla. Dist. Ct. App. 2014) (discussing how 
revoking the license of an over-prescriber relates to a concrete public-health concern). 
 139. See Georgia Prescription Drug Monitoring Program, supra note 15 (discussing the benefits of 
the PDMP); see also Haffajee, supra note 128, at 1655 (“PDMPs bear a real and substantial relation to 
the protection of public health and safety: they aim to inform optimal prescribing as well as to address 
patients and prescribers with outlier fill and prescribing patterns, respectively.”). 
 140. Lewis v. Superior Court, 397 P.3d 1011, 1022 (Cal. 2017). Although the substantive due process 
right in this case was the right to privacy provided by the California Constitution, the case is illustrative 
of how courts find state PDMP laws as important tools for the state in regulating public health. Id. 
 141. Ga. Bd. of Dentistry v. Pence, 223 Ga. App. 603, 604, 478 S.E.2d 437, 440 (1996) (citations 
omitted) (discussing due process in the context of dental licensing). 
 142. Id. 
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Privacy 
The concern surrounding database information privacy is not new; 
legislators voiced their concern when the General Assembly enacted 
the original PDMP laws in 2011.144 Because the new laws are 
mandatory rather than optional, even more patient information will 
be entered into the database, raising additional privacy concerns.145 
The new laws maintain three original safeguards for protecting the 
information.146 First, the law permits disclosure only to certain 
individuals.147 However, the new law allows authorized disclosure to 
more individuals in additional roles.148 Second, the Electronic 
Database Review Advisory Committee still oversees the database’s 
security.149 Third, the law provides substantial penalties to 
individuals who use the information in the database for anything 
other than its intended purpose.150 
Despite these safeguards, individuals continue to have concerns 
over intrusions by three groups: the state government, the federal 
government, and third parties.151 First, patients whose information is 
in the PDMP may be concerned about the state government 
compiling and accessing their prescription history.152 However, in 
1977, the Supreme Court in Whalen v. Roe held that maintaining 
                                                                                                                 
 143. Id. 
 144. Bruff & Daugherty, supra note 12, at 289–90 (discussing the privacy concerns for individuals in 
the database). 
 145. See Tanner Interview, supra note 11, at 13 min., 47 sec. (discussing how, under the Act, more 
individuals are allowed access to the database, but noting that the act also ensures the penalties of a 
felony remain as a deterrent for misuse of the database). 
 146. O.C.G.A. § 16-13-60(c); see also Bruff & Daugherty, supra note 12, at 289–90. 
 147. O.C.G.A. § 16-13-60(c). The statute permits disclosure “only to authorized prescribers or 
dispensers for providing care to a specific patient, upon request by a patient, prescriber, or dispenser 
about whom the information concerns, to law enforcement with a search warrant, or to the Agency or 
Medical Board with an administrative subpoena.” Bruff & Daugherty, supra note 12, at 289. 
 148. O.C.G.A. § 16-13-60(c). The new law increases the PDMP’s efficiency by expanding authorized 
disclosure to include two individuals working with the prescriber or dispenser, two individuals working 
in a healthcare facility where the prescriber is practicing, or two individuals per shift or rotation in an 
emergency department. Id. 
 149. O.C.G.A. § 16-13-61. 
 150. O.C.G.A. § 16-13-64(b), to -(c) (Supp. 2017); Bruff & Daugherty, supra note 12, at 289. 
 151. See Haffajee, supra note 128, at 1647–49 (discussing the state and federal government authority 
to administer PDMPs); Bruff & Daugherty, supra note 12, at 289–90. 
 152. See Whalen v. Roe, 429 U.S. 589, 591 (1977) (discussing a challenge to New York’s Controlled 
Substances Act of 1972 requiring the recording of prescription drug history). 
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prescription databases did not violate the Fourteenth Amendment.153 
In Whalen, a group of concerned patients and physicians challenged 
New York’s use of a prescription database, arguing that collection of 
such data violated the Fourteenth Amendment and may stigmatize 
the patients as “drug addicts” and cause them to avoid medical 
treatment.154 The Court held that these databases are legitimate uses 
of state power and are not an immediate threat of “invasion of any 
right or liberty protected by the Fourteenth Amendment.”155 But even 
though the Supreme Court found compilation of data into databases 
constitutional, another concern may be whether the procedures in 
place for obtaining the information are legal or constitutional—a 
concern not addressed in Whalen.156 
The Georgia General Assembly provided the procedure for state 
law enforcement agencies to access the information in the 2011 
version of the PDMP.157 Code section 16-13-60 provides that state 
officials must obtain a search warrant to access the database.158 
According to the Georgia Department of Public Health guidelines, all 
law enforcement and regulatory agency warrants are subject to 
review pursuant to HIPAA and other state and federal privacy 
laws.159 
Second, individuals may have concerns about the federal 
government accessing personal information found in the database.160 
                                                                                                                 
 153. Id. at 603–04. 
 154. See, e.g., id. at 595. 
 155. Id. at 603–04. 
 156. Tucker v. City of Florence, 765 F. Supp. 2d 1320, 1323 (N.D. Ala. 2011) (discussing a challenge 
to the constitutionality of obtaining information from a PDMP by asserting to the agency that the officer 
had “probable cause”). In Tucker, the Northern District of Alabama found an officer’s mere averment 
that he “had probable cause” was sufficient under Alabama law that required only an “affidavit stating 
probable cause for the use of the requested information.” See id. at 1336–72; see also ALA. CODE 
§ 20-2-214(5) (2011). Alabama subsequently changed the statute to require an “application to the 
department accompanied by a declaration that probable cause exists for the use of the requested 
information.” ALA. CODE § 20-2-214(7) (West, Westlaw through 2017 Reg. Sess.). 
 157. See O.C.G.A. § 16-13-60(c)(3) (Supp. 2017) (stating that a search warrant is required for state 
officials to access information in the database). 
 158. Id. (stating that the Department of Public Health is authorized to provide information “[t]o local 
or state law enforcement or prosecutorial officials pursuant to the issuance of a search warrant . . . or to 
federal law enforcement or prosecutorial officials pursuant to the issuance of a search warrant pursuant 
to 21 U.S.C. or a grand jury subpoena pursuant to 18 U.S.C.”). 
 159. Georgia Prescription Drug Monitoring Program (GA PDMP), GA. DRUGS AND NARCOTICS 
AGENCY https://gdna.georgia.gov/georgia-prescription-drug-monitoring-program-ga-pdmp (last visited 
Sept. 17, 2017). 
 160. See United States v. Zadeh, No. 4:14-CV-106-O, 2014 U.S. Dist. LEXIS 181500, at *2 (N.D. 
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Both versions of Georgia’s PDMP laws require law enforcement 
agencies obtain “search warrant[s] pursuant to 21 U.S.C.” or “grand 
jury subpoena[s] pursuant to 18 U.S.C.” in order to access 
information in the database.161 However, federal courts have recently 
held that mere administrative subpoenas (such as those used by the 
DEA) are sufficient to access the information.162 Therefore, although 
state agencies may be required to show probable cause, federal 
agencies may be able to obtain the information under a lesser 
standard, such as information “reasonably relevant” to an inquiry 
under the agency’s authority.163 
Two cases recently addressed whether administrative subpoenas 
are sufficient for a federal agency to access information in a state 
PDMP.164 On April 21, 2016, the Fifth Circuit upheld the use of the 
“reasonably relevant” standard when deciding whether to enforce an 
administrative subpoena.165 In United States v. Zadeh, a physician 
refused to comply with a subpoena from the DEA asking for medical 
records of the physician’s patients.166 The court sided with five other 
circuit courts by reasoning that: 
[A]n administrative subpoena is enforceable so long as 1) it 
satisfies the terms of its authorizing statute, 2) the 
documents requested were relevant to the [agency’s] 
investigation, 3) the information sought is not already in the 
                                                                                                                 
Tex. Dec. 3, 2014) (discussing a challenge to the constitutionality and legality of the federal government 
using administrative subpoenas to access the data in the database). 
 161. O.C.G.A. § 16-13-60(C)(3) (Supp. 2017). 
 162. See Zadeh, 2014 U.S. Dist. LEXIS 181500, at *25 (holding that individuals have a reduced 
expectation of privacy in the “pervasively regulated industry” of prescription drugs, and the federal 
Controlled Substances Act provides that the federal government may reasonably rely upon 
administrative subpoenas to access information in PDMP databases). 
 163. United States v. Zadeh, 820 F.3d 746, 755 (5th Cir. 2016). “Under the ‘reasonable relevance’ 
standard, courts will enforce an administrative subpoena issued in aid of an investigation if: ‘(1) the 
subpoena is within the statutory authority of the agency; (2) the information sought is reasonably 
relevant to the inquiry; and (3) the demand is not unreasonably broad or burdensome.’” Id. 
 164. See id. at 749; Or. Prescription Drug Monitoring Program v. United States DEA, 998 F. Supp. 2d 
957, 967 (D. Or. 2014), rev’d, No. 14-35402, 2017 U.S. App. LEXIS 11292, at *18 (9th Cir. June 26, 
2017). 
 165. Zadeh, 820 F.3d at 755–56. 
 166. Id. at 749. 
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[agency’s] possession, and 4) enforcing the subpoena will 
not constitute an abuse of the court’s process.167 
The court held that the DEA met the lowered threshold.168 
On June 26, 2017, the Ninth Circuit similarly reversed a decision 
by the District Court for the District of Oregon that held individuals 
have a heightened expectation of privacy regarding their information 
in PDMPs.169 In Oregon Prescription Drug Monitoring Program v. 
United States DEA, the Oregon PDMP refused to comply with a 
subpoena from the DEA because it violated Oregon law requiring “a 
valid court order based on probable cause.”170 The district court sided 
with the PDMP, finding individuals with information in the PDMP 
have a heightened expectation of privacy, and the administrative 
subpoena violated the Fourth Amendment’s probable cause 
requirement.171 The Ninth Circuit reversed, holding the Controlled 
Substances Act (CSA), which allows the DEA to obtain records 
pursuant to an administrative subpoena, preempted the Oregon 
PDMP law requiring a valid court order prior to disclosure of 
prescription records.172 The CSA provides that the Attorney General 
may “require the production of any records . . . which the Attorney 
General finds relevant or material to the investigation.”173 The Ninth 
Circuit concluded that a warrant based on probable cause was not 
required.174 The court reasoned that the Oregon law “interferes with 
the methods by which the federal statute was designed to reach [its] 
goal,” thus making it “an obstacle to the full implementation of the 
CSA.”175 Therefore, although the Georgia PDMP laws require federal 
agencies to show probable cause to access the database, federal 
agencies may be able to rely instead on more easily obtained 
                                                                                                                 
 167. Id. at 757. The court sided with reasoning provided by the Sixth Circuit, but the court further 
stated that “[t]he Third, Fourth, Seventh and Tenth Circuits have also applied versions of the reasonable 
relevance test in upholding administrative subpoenas for medical records.” Id. 
 168. Id. at 758. 
 169. Or. Prescription Drug Monitoring Program v. United States DEA, No. 14-35402, 2017 U.S. App. 
LEXIS 11292, at *16 (9th Cir. June 26, 2017). 
 170. Or. Prescription Drug Monitoring Program v. United States DEA, 998 F. Supp. 2d 957, 960 (D. 
Or. 2014), rev’d, No. 14-35402, 2017 U.S. App. LEXIS 11292, at *18 (9th Cir. June 26, 2017). 
 171. Id. at 967. 
 172. Or. Prescription Drug Monitoring Program, 2017 U.S. App. LEXIS 11292, at *18. 
 173. 21 U.S.C. § 876 (2012). 
 174. Or. Prescription Drug Monitoring Program, 2017 U.S. App. LEXIS 11292, at *18. 
 175. Id. (quoting Gade v. Nat’l Solid Wastes Mgmt. Ass’n, 505 U.S. 88, 103 (1992)). 
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administrative subpoenas that are “reasonably relevant” to their 
investigation.176 The Eleventh Circuit, however, has not yet ruled on 
this issue.177 
Finally, individuals may have concerns about third party access to 
personal information stored in the database.178 The 2011 law that 
created the PDMP also established the Electronic Database Review 
Advisory Committee.179 The Act adds a pharmacist from the State 
Board of Pharmacy and a representative from the Department of 
Public Health to the Advisory Committee.180 Additionally, the new 
law maintains substantial penalties to deter unauthorized use of the 
database.181 Misuse of the database information is a felony carrying 
possible penalties of imprisonment of not less than two years, a fine 
up to $250,000, or both.182 Therefore, the new PDMP laws should 
create a more effective program while maintaining the security of 
patient information across the state.183 
This legislative session, the Georgia Assembly took a step towards 
curbing opioid abuse by shifting the PDMP from a voluntary to a 
mandatory reporting system. The General Assembly knew the 2011 
PDMP did not adequately address the existing opioid problem, and 
this new legislation was an attempt to swing “the pendulum over to a 
substantial step forward” from the previous laws.184 The new laws 
also generate urgency by providing the state medical board the 
authority to hold physicians accountable for failure to check the 
database.185 Although Georgia does not go as far as some states 
where criminal penalties exist for failure to consult the registry,186 
                                                                                                                 
 176. See O.C.G.A. § 16-13-60(a)(3) (Supp. 2017). 
 177. A Lexis Advance and Westlaw search for “PDMP and ‘administrative subpoenas’” returns no 
results for an 11th Circuit opinion on the issue. 
 178. Bruff & Daugherty, supra note 12, at 289 (discussing the concerns over security breaches to 
unauthorized third parties). 
 179. 2011 Ga. Laws 659 (codified at O.C.G.A. § 16-13-61 (Supp. 2017)). 
 180. O.C.G.A. § 16-13-61(b). 
 181. Tanner Interview, supra note 11, at 14 min., 0 sec. (“[W]e still maintain the integrity of 
protecting that information. And that is a felony.”). 
 182. O.C.G.A. § 16-13-64 (Supp. 2017). 
 183. Tanner Interview, supra note 11, at 14 min. 
 184. Id., at 3 min., 45 sec. 
 185. O.C.G.A. § 16-13-63(a)(2)(C). 
 186. See, e.g., Marilyn Schatz, Complying with I-STOP: The New York State Prescription Monitoring 
Program, DATELINE (Med. Liab. Mut. Ins. Co., New York, N.Y.) Fall 2013, at 7, 
https://secure.mlmic.com/pdf/DatelineSpecialEd_FINAL.pdf (discussing New York’s PDMP laws and 
how failure to comply is considered willful misconduct); see also N.Y. Pub. Health § 12-b (2017) 
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this new form of accountability represents a measured step in the 
right direction towards curbing the opioid crisis.187 If the new laws do 
not shift the pendulum far enough to create a positive effect, then 
some legislators are willing to revisit the PDMP laws in the future.188 
Only time will tell if the cumulative effects of the Act’s measured 
approach are enough to mitigate one of our nation’s largest health 
care crises. 
Emily R. Polk & Brandon M. Reed 
                                                                                                                 
(discussing a possible $2,000 fine and up to one year imprisonment for willful misconduct). 
 187. Tanner Interview, supra note 11, at 3 min., 30 sec. 
 188. Id., at 3 min., 50 sec. (“Let’s monitor that and see if it’s enough; and if it’s not enough, then 
we’ll take additional steps in the future.”). 
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